Longevium raises $7 million to build an AI-powered longevity lab in Dubai

The round Longevium has raised $7 million to build an AI-powered longevity lab in Dubai, according to Wamda . The facility is set to be based in Dubai Science Park, a hub for life-sciences and healthcare companies operating in the emirate. Longevium's model combines longevity medicine — a growing field focused on extending healthy lifespan through diagnostics, monitoring and personalised interventions — with artificial intelligence used to analyse health data and generate insights that a purely manual clinical process would struggle to produce at the same speed or scale. The pairing of clinical infrastructure with an AI analysis layer is what distinguishes Longevium's approach from a traditional diagnostics clinic offering similar tests without the same data-driven interpretation. Why Dubai, and why now Dubai Science Park's concentration of life-sciences infrastructure gives Longevium access to a built-in ecosystem of healthcare and research-adjacent companies, along with regulatory familiarity for operating a clinical or diagnostics-facing facility in the emirate. The choice of location reflects a broader pattern of longevity and advanced healthcare startups gravitating toward Gulf hubs that combine research infrastructure with high-net-worth consumer demand for personalised health services. Longevity medicine has grown globally as a category over recent years, driven by advances in diagnostics and data analysis that make it possible to detect early markers of age-related decline well before symptoms would otherwise appear. Building that capability with AI at the core, rather than as an add-on, is central to Longevium's pitch, and a dedicated physical lab gives it more control over data quality and testing consistency than partnering with third-party diagnostic labs would allow. Part of a broader Gulf healthtech wave Longevium's raise adds to a wave of health-adjacent technology funding across the Gulf this year, a category that also includes Enhance's $18.2 million raise combining equity and venture debt, covered in TechScoop's report on that round . Both deals reflect investor interest in health-adjacent technology businesses. The broader question of where AI is actually creating value in Gulf healthcare — beyond pilots and announcements — is explored further in TechScoop's analysis of AI's real-world use in the region's healthcare sector , a lens that applies directly to how Longevium's lab is positioned, since its core value proposition depends on AI analysis translating into genuinely actionable clinical insight rather than a marketing feature layered onto standard diagnostics. What's next With $7 million secured, Longevium's next step is standing up the physical lab in Dubai Science Park and building out the clinical and AI capabilities it has raised capital to develop. The company has not disclosed a specific timeline for the lab's opening or the initial services it plans to offer, but building physical, regulated healthcare infrastructure typically takes longer than launching a purely digital health product, which will likely shape how quickly Longevium can move from this funding announcement to an operating facility. Longevity medicine's Gulf appeal The Gulf's combination of high disposable income among a segment of consumers, growing interest in preventive and personalised healthcare, and government-backed investment in life-sciences infrastructure has made the region an increasingly attractive base for longevity-focused healthcare businesses, even though the underlying science of longevity medicine remains an active and, in places, still-developing area of research globally. Companies entering this space are, in effect, betting that demand for advanced preventive diagnostics will grow faster in wealthy Gulf markets than the pace at which the broader scientific evidence base matures — a bet that has proven commercially viable in other affluent markets that have supported similar longevity clinics and diagnostics providers. For Longevium specifically, positioning its lab around AI-driven analysis, rather than diagnostics alone, is an attempt to differentiate from more conventional preventive-health clinics that may offer similar blood work and screening without the same data-analysis layer built specifically to interpret it. The company's funding also arrives as more investors globally look for healthtech businesses that combine a physical, regulated service with a defensible data or software layer, rather than backing purely app-based wellness products whose differentiation can be easier for competitors to copy. A physical lab paired with proprietary AI analysis is, in that sense, a harder business to replicate quickly than a standalone app, even if it is also more expensive and slower to build. Sources Wamda